Navigation Links
GlaxoSmithKline's Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
Date:1/20/2009

An Agent Showing Improvement in Overall Response Rate Would Earn Higher Patient Share in U.S. Than Europe, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline's ofatumumab will become Decision Resources' proprietary clinical gold-standard treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) by 2012. This shift is due to ofatumumab's competitive advantages over the current gold standard--Bayer Schering Pharma's Campath/MabCampath--in efficacy (overall response rate), safety and tolerability (hematological toxicities and infections) and delivery (frequency).

The new report entitled Relapsed/Refractory Chronic Lymphocytic Leukemia: Physicians Are Eager for Increasingly Efficacious Therapies in the Refractory Setting finds that an agent showing improvement in overall response rate, compared to Campath/MabCampath, for high-risk, relapsed/refractory patients would earn a higher patient share in the U.S. (50 percent) than in Europe (40 percent). This is because European oncologists are more cost-conscious than U.S. physicians and such a drug would bear a slight price increase.

"The European market is more sensitive to increases in price than the U.S. market, and the price of Campath/MabCampath is already very high in both markets. Even though European oncologists forecast a more conservative patient share for such an agent, a patient share of 40 percent is considerable in the relapsed/refractory CLL market," stated Andrew Merron, Ph.D., analyst at Decision Resources.

About the Report

Relapsed/Refractory Chronic Lymphocytic Leukemia: Physicians Are Eager for Increasingly Efficacious Therapies in the Refractory Setting is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador
2. Zumas Rescue Ranch becomes a Federal 501C3
3. MinuteClinic Becomes Participating Provider With Blue Cross and Blue Shield of Florida
4. Medscape Physician Connect Becomes Largest Online Physician Social Network with More than 100,000 Physicians
5. Dental Network of America Becomes Largest National Dental Network in the U.S.
6. Mega Pediatric Group Allows Doctors to Focus on Patient Care as the Business Side of Private Practice Becomes More Difficult to Sustain
7. When the Caregiver Becomes the Patient
8. K-State helps nursing home staff become comfortable with residents sexual expression
9. 26 percent of sleepless children become overweight
10. Two Colorado Surgeons Become Pioneers In Microsurgical DIEP Flap Breast Reconstruction
11. Coors of Las Vegas Becomes New Distributor of RecoveryX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: